OSTX (OS Therapies) Other Current Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTX OS Therapies Inc OSTX
10 GF Score
Price $1.53
! 4 Warning Signs
View Full Analysis

What is OS Therapies Other Current Liabilities?

OS Therapies OSTX +0.63% 10 Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates OSTX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

OS Therapies's other current liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

OS Therapies's annual other current liabilities declined from Dec. 2023 ($4.71 Mil) to Dec. 2024 ($1.97 Mil) and declined from Dec. 2024 ($1.97 Mil) to Dec. 2025 ($0.00 Mil).

OS Therapies Other Current Liabilities Related Terms

OS Therapies Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for OS Therapies's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OS Therapies Other Current Liabilities Chart

OS Therapies Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
1.61 3.04 4.71 1.97 0.00

OS Therapies Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 0.00 0.00 0.00 0.00
OSTX
10GF Score
OS Therapies Inc OSTX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OS Therapies Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
OS Therapies (OSTX) has a Other Current Liabilities of $0.00 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OS Therapies.
Is OS Therapies' Other Current Liabilities too high?
OS Therapies' current Other Current Liabilities is $0.00 Mil. Overall, OS Therapies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does OS Therapies' Other Current Liabilities compare to RNTX and BSEM?
OS Therapies' Other Current Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OS Therapies. OS Therapies's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OS Therapies stock overvalued right now?
OS Therapies (OSTX) has a current Other Current Liabilities of $0.00 Mil. The current Other Current Liabilities is $0.00 Mil. OS Therapies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For OS Therapies (OSTX), the current Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OS Therapies Business Description

Address 115 Pullman Crossing Road, Suite 103, Grasonville, MD, USA, 21638
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
10GF Score

Get the complete analysis for OSTX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.53
Price